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type 2 diabetic patients above 18 years who underwent QST using computer-
driven Medoc TSA II NeuroSensoryAnalyzer system from a period of October 
2011 to May 2012. The results of QST were compared to those of monofilament 
test. RESULTS: Ninety-nine patients (73 males, 26 females) with an average age 
51.49±11.07 years (range: 18-76 years) were recruited in the study. The sensitivity 
and specificity of QST to determine Warm Sensation Threshold, Cold Sensation 
Threshold, Heat Pain Threshold and Cold Pain Threshold in comparison to 
monofilament test was found to be maximum in case of Warm Sensation 
Threshold (86% and 94.5%, respectively). Cold Sensation Threshold was found to 
be inversely proportional to HbA1c (correlation=-0.0909) as well as age 
(correlation=-0.4395). It was also seen that Cold PainThreshold was inversely 
proportional to age (correlation=-0.2143) and Heat Pain Threshold was directly 
proportional to age (correlation=0.2698). CONCLUSIONS: Taking into 
consideration, the high sensitivity and specificity of quantitative sensory testing 
in case of Warm Sensation Threshold and limitations of our study, we conclude 
that Quantitative Sensory Testing can be of use in detecting diabetic peripheral 
neuropathy if used in proper way.  
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OBJECTIVES: High rates of undiagnosed chronic kidney disease (CKD) in type-2 
diabetics (T2DM) indicate that it may not take priority relative to other 
comorbidities. This study examined the prevalence and costs of stage 3-5 CKD in 
relation to other comorbidities within an insured patient population. METHODS: 
Medical and pharmacy claims and laboratory results from a US commercially-
insured population were used to identify patients aged 18-64 with T2DM from 
2006-2010 (the first observed diagnosis as the index date), continuous follow-up 
for 12 months following the index date, and a serum creatinine finding. 
Comorbid hypertension, dyslipidemia, heart diseases/stroke, eye problems, and 
neuropathy were identified during the post-index period based on diagnosis 
codes. Stage 3-5 CKD was identified by medical claims or laboratory findings 
with glomerular filtration rate <60 mL/min/1.73m2. Annual total health care costs 
were reported at follow-up for the selected comorbidities. Generalized linear 
regression models were used to estimate the incremental costs of a given 
comorbidity. RESULTS: The final study sample included 101,964 T2DM patients 
(47.7% hypertension; 53.5% dyslipidemia; 9.7% heart diseases/stroke; 11.6% eye 
problems; 7.0% neuropathy; 9.2% stage 3-5 CKD). The direct annual total mean 
health care costs were $13,158 for all T2DM patients and were as follows for the 
selected comorbidities: hypertension: $16,676; dyslipidemia: $13,537; heart 
diseases and stroke: $39,987; eye problems: $16,017; neuropathy: $24,563; and 
stage 3-5 CKD: $28,325. After adjustment, the incremental costs of these selected 
comorbidities were $2,650, -$545, $17,752, $587, $6,043, and $7,792, respectively 
(all p<0.01). CONCLUSIONS: Among the commercially insured diabetics, the 
prevalence of CKD is similar to heart diseases/stroke, eye problems and 
neuropathy and had the second highest annual health care costs after heart 
diseases/stroke. The burden associated with moderate to severe CKD indicates 
that it should be considered as much as other comorbidities in the care of T2DM 
patients  
 
PDB83  
FREQUENCIES OF SELF-MEASUREMENT OF BLOOD GLUCOSE ACCORDING TO 
DIABETES TYPE AND TREATMENT  
Ruiz L1, Lammert M2, Colclough H1 
1Adelphi Real World, Bollington, UK, 2NovoNordisk, Copenhagen, Denmark  
OBJECTIVES: Self-Measurement of Blood Glucose (SMBG) is an important part  
of good diabetes management. Guidelines suggest frequent SMBG testing (the 
number depending on type of diabetes treatment), but there are also limitations 
in some countries on the maximum number of reimbursed strips per month. 
Each SMBG strip costs approximately 0.5€. Limited information on frequency  
of SMBG exists, although it accounts for a considerable proportion of diabetes 
management costs. METHODS: Data were drawn from the 2012 Adelphi Diabetes 
Disease Specific Programme, a cross-sectional survey involving 374 primary  
care physicians and 256 specialists across Europe. Doctors completed patient 
record forms for 7528 consulting patients, 4839 of whom independently 
completed a self-completion questionnaire. SMBG testing frequency was 
analysed separately for type-1 (T1) and type-2 (T2) diabetics and type of 
treatment (non-insulins, basal-only treatment (BOT), basal-bolus (BB) and other 
insulins). RESULTS: Proportion of patient-reported SMBG, T1 93.7%, T2 BOT 
81.0%,T2 BB 88.7%. Physicians reported similar proportions of patients measuring 
their own glucose (T1 94.8%, T2 BOT 79.8% and T2 BB 90.3%). Physician 
recommended SMBG testing between (mean) 31.5 (T2 non-insulins) and 92.4 (T1) 
tests per month with 48.7 for T2 BOT, 81.0 for T2 BB users. The actual mean 
number of patient-reported SMBG tests per month is between 28.8 (T2 non-
insulins) and 94.1 (T1), with 43.4 for T2 BOT, 83.5 for T2 BB.There is thus high 
consistency between patient and physician responses on proportion of patients 
performing SMBG and frequency of testing per month. CONCLUSIONS: Diabetes 
patients appear to accurately follow the SMBG recommendation from their 
physician. Insulin-treated diabetes is associated with frequent SMBG testing, and 
testing frequency increases with number of daily insulin injections. Treatment 
and technologies that can reduce the need for SMBG without compromising 
overall diabetes management could help to reduce overall diabetes management 
costs.  
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OBJECTIVES: To assess the effect of statins on change in renal functions in 
patients with diabetic kidney disease (DKD). METHODS: Medline, Cochrane 
Central Register of Controlled Trials, SCOPUS, PsycINFO, and Web of Science 
databases were searched using the search terms that included Medical Subject 
Headings (MeSH) terms as well as text words. Randomized controlled (either 
parallel or crossover design) trials (RCTs), or quasi-randomized controlled trials 
of statins compared with placebo, other statins, or other drugs conducted in 
patients with either Type 1 or Type 2 DKD were included. We excluded studies in 
patients with kidney injury due to disease other than diabetes mellitus (such as 
gestational diabetes), patients on dialysis and/or with end-stage renal disease, 
and non-English articles. The primary endpoints were the rate of change in 
estimated Glomerular Filtration Rate (GFR) (ml/min) and the change in urine 
albumin excretion rate (AER) from baseline to follow-up. The quality of the 
studies was assessed using risk of bias assessment tool. RESULTS: The search 
yielded 738 studies of which 12 studies, with 3559 patients aged 18 years or older, 
were included. Statins comprised of atorvastatin (n=2), simvastatin (n=5), 
rosuvastatin (n=2), fluvastatin (n=1), lovastatin (n=1), and pravastatin and 
pitavastatin (n=1). The mean duration of follow-up was 15.75 months. Six of the 
studies were double-blinded. The studies were heterogeneous in design, 
treatment, dose and duration of follow-up. In six studies statins either 
significantly reduced albuminuria or prevented the rise of albuminuria. In five 
studies statin use retarded the deterioration of GFR. Thus, statins showed 
modest beneficial effect on renal functions in patients with DKD. CONCLUSIONS: 
Statins may delay the progression of kidney disease in diabetic patients. 
However, additional studies with larger sample size and longer duration of 
treatment are needed to confirm the beneficial effect of statins in patients with 
DKD.  
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OBJECTIVES: The likelihood of reaching A1C treatment targets using 
monotherapy with antihyperglycemic agents (AHAs) is low in patients (pts) with 
type 2 diabetes (T2DM) and moderately elevated A1C levels. AACE/ACE 
guidelines recommend initiating dual therapy (DT) with AHAs in untreated pts 
with an A1C 7.6 – 9.0%. This analysis was to estimate the proportion of 
treatment-naïve pts with T2DM and an A1C 7.6 – 9% who initiate AHA treatment 
with DT and associated pt-related factors. METHODS: Using GE EMR database, 
pts included had a T2DM diagnosis from 2003 to 2010, ≥1 A1C measurement 7.6 – 
9.0% (first instance = index date), continuous enrollment for ≥12 months before 
and ≥6 months after index date, and no AHA prescriptions in one year prior to 
index date. Pts receiving AHA prescriptions for DT within 30 days of index date 
were considered to have initiated DT at index date. Logistic regression identifies 
factors associated with initiating DT. RESULTS: Of the 30,501 selected pts, 8% 
initiated AHA DT and 36% initiated monotherapy within 30 days of the index 
date. After adjusting for baseline, pts with T2DM and an A1C 7.6 – 9.0% were 
more likely to initiate AHA DT if they had higher A1C (adjusted OR = 1.78 [95% CI: 
1.61, 1.97]). Pts were less likely to be prescribed AHA DT if they were older (per 5-
year OR = 0.95 [0.92, 0.97]), lived in regions outside of the South (ORs ranged from 
0.44 – 0.68 for different regions compared to South), or had chronic renal 
disease/renal failure (OR [95% CI] = 0.46 [0.28, 0.76]). CONCLUSIONS: In summary, 
in a cohort of untreated pts meeting AACE/ACE guideline recommendation for 
initiating DT, the proportion of pts initiating DT (8%) or any AHA regimen (44%) 
was low. More strenuous efforts are needed to address underutilization of AHAs 
and appropriate use of DT.  
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OBJECTIVES: We estimated economic burden associated with emergency 
department (ED) visits and outpatient/ambulatory visits for hypoglycemia for 
year 2005-2009. METHODS: We analyzed the National Hospital Ambulatory 
Medical Care Survey (NHAMCS) and the National Ambulatory Medical Care 
Survey (NAMCS). The NHAMCS has ED and outpatient department (OPD) 
components. The unit cost can be estimated from the Medical Expenditure Panel 
Survey (MEPS) for patients with diabetes (n=1010 in 2005, 1115 in 2006, 1039 in 
2007, 1164 in 2008, 1276 in 2009). The annual costs were estimated by the 
multiplication of the MEPS unit costs and annual NHAMCS and NAMCS health 
care utilization associated with hypoglycemia. We did not estimate the annual 
hospitalization costs in NHAMCS OPD and the NAMCS due to no information on 
length of stay. All costs were adjusted to the U.S. 2009 dollars. RESULTS: The 
MEPS unit cost increased from $692 in 2005 to $932 in 2009, the annual 
expenditure of hypoglycemia ED visits fluctuated between $339 million in 2007 
and $400 million in 2006 due to the estimated total hypoglycemia visits declined 
over those 5 years. Hospital admissions from emergency department associated 
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with hypoglycemia ED visits was in a declining trend of 2005-2009 and the lowest 
in 2009 (n=71,751). Consequently, the estimated annual expenditure of hospital 
admission from ED declined each year from 2005 ($2.90 billion) to 2009 ($1.25 
billion). The expenditure of hypoglycemia visits to ambulatory facilities 
fluctuated between 0.37 million in 2007 and 1.08 million in 2008, resulting in the 
estimated annual cost of approximately $80.46 million to $229.03 million, 
respectively. CONCLUSIONS: Annual direct medical cost associated with 
hypoglycemia in the U.S. was $3.49 billion in 2005 and declined to $1.84 billion in 
2009. The trend may be attributed to improvements in patient education, glucose 
monitoring, and new anti-diabetic medications with lower risk for hypoglycemia.  
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OBJECTIVES: To compare overall and diabetes-related health care utilization and 
expenditures in Medicare beneficiaries with diabetes prior to and after 
implementation of Part D. METHODS: Data were from the 2001-2010 Medical 
Expenditure Panel Survey. Medicare beneficiaries aged ≥65 years with self-
reported diabetes were identified, excluding individuals who were Medicare-
Medicaid dual eligible, had TRICARE, or other public coverage. The outcomes 
included overall and diabetes-related prescriptions, medical services utilization, 
and expenditures as well as out-of-pocket costs. These outcomes were analyzed 
using generalized linear model regression models with a log-link and gamma (for 
costs) or Poisson (utilization) distribution. All expenditures were inflated to 2010 
dollars. STATA survey commands were used to account for the complex survey 
design. RESULTS: There were 21,864 eligible Medicare beneficiaries with diabetes 
that comprised the sample population. After adjusting for sociodemographic 
characteristics and health status, implementation of Part D was associated with 
decreased out-of-pocket expenditures for insulin (Coeff.: -0.577, p<0.05) and oral 
antidiabetic agents (Coeff.:-1.292, p<0.001). No statistically significant effect on 
total health care and prescription expenditures were found. Implementation of 
Part D was associated with increased number of prescriptions filled (Coeff.: 0.145, 
p<0.001) without increase in emergency room visits or inpatient stays. 
CONCLUSIONS: The implementation of Medicare Part D increased medication 
use and reduced out-of-pocket costs for elderly diabetes patients. This reduction 
would allow for enhanced access to necessary medications, and thereby may 
have a positive impact on adherence and health outcomes.  
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OBJECTIVES: To determine the factors associated with prescription drug 
expenditure in patients with Diabetes Mellitus in the United States (US). 
METHODS: A retrospective cross-sectional study was conducted using the 2005-
2009 Medical Expenditure Panel Survey (MEPS) data, a nationally representative 
data on non-institutionalized US population. The study sample included diabetic 
patients identified using the diabetes diagnosis variable reported in the MEPS 
data and the ICD-9CM code: 250. Descriptive statistics were performed on the 
weighted sample to estimate the average prescription drug expenditure for 
patients with Diabetes. The Anderson Behavioral Model was used as the 
theoretical framework to identify factors associated with prescription drug 
expenditure and Ordinary Least Square regression was used for analysis. The 
prescription drug expenditure was log transformed to address skewed nature of 
cost data. RESULTS: An estimated 97 million patients were diagnosed with 
Diabetes Mellitus during 2005-2009. The average prescription drug expenditure 
for these patients was $3088 per year (95% CI: 2977-3199). The linear regression 
revealed that predisposing (age, race, marital status and employment status), 
enabling (region, health insurance coverage, prescription insurance coverage and 
usual source of care) and need (Charlson comorbidity index and general health 
status) characteristics were significantly associated with prescription drug 
expenditure. One year increase in age increased expenditure by 1.1%. Non-
Hispanic blacks had 33% higher expenditure than other races. Patients with 
health insurance coverage, prescription insurance coverage and usual source of 
care had 54%, 13% and 69% higher expenditure respectively as compared to 
those without these benefits. Charlson comorbidity index was positively 
associated with prescription drug expenditure. Patients with poor/fair self-
reported health status had 61% higher expenditure than other patients. 
CONCLUSIONS: Predisposing and enabling factors like race, employment, health 
and prescription insurance coverage and usual source of care had significant 
impact on prescription expenditure despite controlling for health status and 
need characteristics.  
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OBJECTIVES: To evaluate the impact of adherence to insulin therapy on health 
resource utilization (HRU) among patients with type 2 diabetes mellitus (T2DM) 
using an insulin pen. METHODS: The Truven Health MarketScan Research 
Database was used to identify patients with ≥1 one insulin pen claim between 
January 2006 and September 2010 with continuous enrollment for 12 months 
after that claim, had a diagnosis of T2DM and one prescription for an oral anti-
diabetic drug. Patient demographics, clinical characteristics, health care 
expenditures and medication (insulin pen) possession ratios (MPR) were also 
analyzed. Total costs were calculated by summing the patient and payer 
portions of all post-index health insurance claims. MPR was calculated using the 
days supply field of the insulin prescription claims, adjusted to account for 
variations in time between insulin refills. RESULTS: 32,361 patients met the 
study criteria. On average patients were 59.1 (SD=11.6) years old and 52.4% were 
male; 97.1% of the sample had capitated, non-capitated or a fee-for-service 
health plan (2.8% unknown). The baseline Charlson comorbidity score was 2.0 
(SD=1.7). The most common comorbidities included hypertension (46.7%), 
dyslipidemia (31.3%), ischemic heart disease (23.4%), diabetic neuropathy (19.6%), 
and renal disease (15.9%). Concomitant medication use was prevalent with at 
least one quarter of the sample filling a prescription for one or more of the 
following: sulfonylureas (27.1%), antidepressants (30.9%), biguanides (48.4%), 
antihyperlipidemics (77.8%) and antihypertensives (87.0%). All-cause 
expenditures for insulin pen users during the study period were $24,680 
(SD=$44,005). Average sample MPR was 0.63 (SD=0.29). When broken into 
quintiles there is a significant difference in health care expenditures between 
the least adherent (MPR 0-0.20, $26,310) and most adherent groups (MPR 0.81-
1.00, $23,839) (p=0.007). CONCLUSIONS: Managing patient adherence may 
present an opportunity to curb health resource utilization in T2DM insulin pen 
users.  
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OBJECTIVES: To examine the economic outcomes associated with dual-goal 
achievement of reaching glycated hemoglobin (HbA1c <7%) and low-density 
lipoprotein cholesterol (LDL-C <100mg/dL) targets in patients with type 2 
diabetes mellitus (T2DM). METHODS: Adult T2DM patients (ICD-9 codes: 250.x0, 
250.x2) were identified from the South Central Veterans Affairs Health Care 
Network (01/2004-06/2010) and followed until the end of data or death. A 
longitudinal design was adopted with patient information recorded in six-month 
cycles. Goal achievement status in each cycle was determined based on the 
average HbA1c and LDL-C levels using the area under the curve method. 
Economic outcomes included diabetes-related utilization events (inpatient (IP) 
days, number of outpatient (OP) visits) and diabetes-related medical service 
costs. The association between goal achievement status in a given study cycle 
and economic outcomes in the following cycle were assessed using multivariate 
generalized linear models, controlling for within-patient correlation. RESULTS: A 
majority of the 75,646 patients selected for the study were male (97.4%); average 
age was 64.7 years, mean BMI was 31.6 kg/m2, and median follow-up time was 
4.5 years. Compared with achievement of only the LDL-C goal, dual-goal 
achievement was associated with significantly fewer diabetes-related IP days 
(Incidence Rate Ratio (IRR): 0.93; 95% Confidence Interval (CI): 0.87-1.00), and OP 
visits (IRR: 0.88; CI: 0.87-0.89), and incurred significantly lower diabetes-related 
medical service costs (difference: -$130.89, p=0.02). Compared with achievement 
of only the HbA1c goal, dual-goal achievement was associated with significantly 
fewer OP visits (IRR: 0.98; CI: 0.97-1.00) but no statistical difference in the number 
of hospitalization days (IRR: 0.98, CI: 0.89-1.07) or diabetes-related medical 
service costs (difference:-$56.17, p=0.40). CONCLUSIONS: In this study of US 
Veterans with T2DM, dual-goal achievement was associated with fewer 
utilization events and lower costs when compared with only LDL-C goal 
achievement.  
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OBJECTIVES: The primary aim was to examine the economic outcomes 
associated with long-term adherence to oral diabetes medications in the 
Diabetes Mellitus (DM) population. The secondary aim was to examine the 
economic outcomes associated with having a history of an HbA1c test during the 
study period. METHODS: Patients continuously enrolled from January 01, 2006 to 
December 31, 2011 and did not have a diabetes diagnosis or medication one year 
prior to the index date were eligible for inclusion in this retrospective study 
(N=2090). Patients who had at least two oral diabetes medication fills in the 
index year, had an integrated medical and pharmacy benefit, and who did not 
have any injectable medications during the study period were stratified to 
examine the primary aim (N=781). Patients were defined as adherent if they had 
a medication possession ratio (MPR) of greater than 80% in all five years (N=153), 
the remainder were classified as non-adherent (N=628). To quantify the 
economic outcomes associated with a history of an HbA1c test, patients were 
stratified based on a history of HbA1c test. RESULTS: Compared to the non-
adherent group, the adherent group had lower unadjusted mean medical costs. 
The five-year total medical costs were $25,726 in the non-adherent group and 
$22,153 in the adherent group, a 16% difference (p≤0.05). A similar difference was 
observed when comparing inpatient and emergency room costs ($8694 vs. $5268, 
p≤0.001) Compared to patients without an HbA1C test during the study period 
(N=792), patients with an HbA1c test (N=1298) had lower total medical costs 
($36,599 vs. $29,153 respectively, p≤0.05) and inpatient and emergency room 
